Although the initial data have shown that the greatest benefit is achieved in the TN breast cancer subtype, PD-L1 positivity is occasionally found in all metastatic breast cancer subtypes, including the HER2-positive subgroup [114]. This evidence concerns the gene ERBB2 and breast cancer.